- Home
- ATYR vs JHI Comparison
ATYR vs JHI Comparison
Compare ATYR & JHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- JHI
- Stock Information
- Founded
- ATYR 2005
- JHI 1971
- Country
- ATYR United States
- JHI United States
- Employees
- ATYR N/A
- JHI N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- JHI Trusts Except Educational Religious and Charitable
- Sector
- ATYR Health Care
- JHI Finance
- Exchange
- ATYR Nasdaq
- JHI Nasdaq
- Market Cap
- ATYR 126.3M
- JHI 121.0M
- IPO Year
- ATYR 2015
- JHI N/A
- Fundamental
- Price
- ATYR $2.12
- JHI $14.36
- Analyst Decision
- ATYR Strong Buy
- JHI
- Analyst Count
- ATYR 4
- JHI 0
- Target Price
- ATYR $19.25
- JHI N/A
- AVG Volume (30 Days)
- ATYR 555.8K
- JHI 29.5K
- Earning Date
- ATYR 11-07-2024
- JHI 01-01-0001
- Dividend Yield
- ATYR N/A
- JHI 6.80%
- EPS Growth
- ATYR N/A
- JHI N/A
- EPS
- ATYR N/A
- JHI 1.05
- Revenue
- ATYR $588,000.00
- JHI N/A
- Revenue This Year
- ATYR N/A
- JHI N/A
- Revenue Next Year
- ATYR $2,057.88
- JHI N/A
- P/E Ratio
- ATYR N/A
- JHI $12.47
- Revenue Growth
- ATYR N/A
- JHI N/A
- 52 Week Low
- ATYR $1.08
- JHI $11.63
- 52 Week High
- ATYR $2.50
- JHI $13.40
- Technical
- Relative Strength Index (RSI)
- ATYR 69.53
- JHI 81.13
- Support Level
- ATYR $1.83
- JHI $13.73
- Resistance Level
- ATYR $1.96
- JHI $14.15
- Average True Range (ATR)
- ATYR 0.09
- JHI 0.10
- MACD
- ATYR 0.03
- JHI 0.03
- Stochastic Oscillator
- ATYR 86.27
- JHI 83.56
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.